Olanzapine + Fluoxetine + Lamotrigine

ApprovedCompleted
0 views this week 0 watching Active
Interest: 43/100
43
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
Phase 3
5
Approved
Indication / Disease

Bipolar Disorder

Conditions

Bipolar Disorder

Trial Timeline

Nov 1, 2003 → Jan 1, 2005

About Olanzapine + Fluoxetine + Lamotrigine

Olanzapine + Fluoxetine + Lamotrigine is a approved stage product being developed by Eli Lilly for Bipolar Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT00485771. Target conditions include Bipolar Disorder.

What happened to similar drugs?

20 of 20 similar drugs in Bipolar Disorder were approved

Approved (20) Terminated (3) Active (0)
Olanzapine + PlaceboEli LillyApproved
OlanzapineEli LillyApproved
OlanzapineEli LillyApproved
olanzapine + risperidoneEli LillyApproved
Topiramate + PlaceboEli LillyApproved

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00485771ApprovedCompleted

Competing Products

20 competing products in Bipolar Disorder

See all competitors
ProductCompanyStageHype Score
OlanzapineEli LillyPhase 3
32
Valproate + Lithium + Risperidone + OlanzapineEli LillyPhase 3
40
Olanzapine + PlaceboEli LillyApproved
43
FK949EAstellas PharmaPhase 3
40
FK949EAstellas PharmaPhase 3
40
FK949E + PlaceboAstellas PharmaPhase 2/3
38
Escitalopram + Bupropion XLLupin LimitedPhase 3
32
OlanzapineEli LillyApproved
43
Olanzapine Hydrochloride + Lithium CarbonateEli LillyPhase 3
40
olanzapine + lithium + valproate + carbamazepineEli LillyPhase 3
40
OlanzapineEli LillyApproved
43
OlanzapineEli LillyPhase 3
40
LY2979165 + PlaceboEli LillyPhase 1
29
olanzapine + divalproex sodium + placeboEli LillyApproved
43
olanzapine + risperidoneEli LillyApproved
43
LY2979165 + placeboEli LillyPhase 1
29
Topiramate + PlaceboEli LillyApproved
43
olanzapineEli LillyPhase 3
40
Olanzapine + PlaceboEli LillyPhase 3
40
Brenipatide + PlaceboEli LillyPhase 2
42